4 completed, 2 unknown, 1 terminated. 4 Phase 4, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Unknown 2, Completed 1, Terminated 1 |
| Phase 3 | 2 | Completed 2 |
Follow symtuza: new trials by email Literature Review of symtuza trials Research Report on symtuza
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Biktarvy & Symtuza on microRNAs in HIV and Correlation With Weight Gain Biktarvy, Symtuza - HIV Infections, Obesity | Phase 4 | Unknown | East Carolina University | 30 | 2023-03-14 | 2023-11-14 |
| Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat' Biktarvy, Symtuza - Human Immunodeficiency Virus | Phase 3 | Completed | Chelsea and Westminster NHS Foundation Trust | 36 | 2020-09-30 | 2024-02-08 |
| Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita) Symtuza - Human Immunodeficiency Virus | Phase 4 | Terminated | Midland Research Group, Inc. | 1 | 2019-09-17 | 2024-09-19 |
| The Late Presenter Treatment Optimisation Study Biktarvy, Symtuza - HIV/AIDS | Phase 3 | Completed | NEAT ID Foundation | 447 | 2019-03-05 | 2025-12-17 |
| A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c) Symtuza® (TAF/FTC/DRV/c), ABC/3TC/DTG + Symtuza® (TAF/FTC/DRV/c) - HIV Infections | Phase 4 | Completed | Fundacion SEIMC-GESIDA | 78 | 2018-12-04 | 2022-06-22 |
| An Italian Observation of Antiretroviral Treatment in Participants Taking Darunavir/ Cobicistat Plus Emtricitabine and Tenofovir Alafenamide Fumarate D/C/F/TAF Fixed-Dose Combination (FDC) - Human Immunodeficiency Virus (HIV) | Completed | Janssen-Cilag S.p.A. | 246 | 2018-06-13 | 2024-10-15 | |
| Implication for Strategies of Long Term Control of Viral Replication in Patient With Primary HIV Infection (PHI). SYMTUZA, DESCOVY+DOLUTEGRAVIR, SYMTUZA+DOLUTEGRAVIR - HIV-1-infection | Phase 4 | Unknown | ADRIANO LAZZARIN, MD | 112 | 2018-05-07 | 2020-01-13 |
Acquired Immunodeficiency Syndrome (4) · HIV Infections (2) · Obesity (1)
ADRIANO LAZZARIN, MD (1) · Chelsea and Westminster NHS Foundation Trust (1) · East Carolina University (1) · Fundacion SEIMC-GESIDA (1) · Janssen-Cilag S.p.A. (1) · Midland Research Group, Inc. (1) · NEAT ID Foundation (1)
Italy (3) · Spain (2) · United Kingdom (2) · United States (2) · Belgium (1) · France (1) · Germany (1) · Ireland (1)
Anthony Ciesielski, MD (1) · Georg Behrens (1) · Marta Boffito, MD PhD FRCP (1) · Paul Cook, MD (1)
PMID 37752816, PMID 39763430, PMID 41344354, PMID 41764532
2019 (1)